ALRN Aileron Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALRN

Price (delayed)

$4.99

Market cap

$84.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.42

Enterprise value

$67.4M

Aileron Therapeutics Inc. is a clinical-stage biopharmaceutical company that is focused on enabling patients to fight cancer without the fear or burden of chemotherapy-induced side effects. The company believes selective ...

Highlights
The EPS is up by 43% year-on-year but it is down by 20% since the previous quarter
Aileron Therapeutics's net income has increased by 42% YoY but it has decreased by 22% from the previous quarter
Aileron Therapeutics's equity has shrunk by 63% YoY and by 38% QoQ
ALRN's quick ratio is down by 47% QoQ and by 37% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aileronrx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ALRN
Market
Shares outstanding
16.97M
Market cap
$84.69M
Enterprise value
$67.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$15.73M
EBITDA
-$15.61M
Free cash flow
-$19.77M
Per share
EPS
-$3.42
Free cash flow per share
-$4.3
Book value per share
$1.52
Revenue per share
$0
TBVPS
$4.45
Balance sheet
Total assets
$106.01M
Total liabilities
$7.71M
Debt
$48,000
Equity
$6.89M
Working capital
$13.88M
Liquidity
Debt to equity
0.01
Current ratio
4.17
Quick ratio
3.95
Net debt/EBITDA
1.11
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-42%
Return on equity
-139.4%
Return on invested capital
-1,583.5%
Return on capital employed
-15.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALRN stock price

How has the Aileron Therapeutics stock price performed over time
Intraday
5.05%
1 week
17.41%
1 month
-19.52%
1 year
244.19%
YTD
63.68%
QTD
-24.74%

Financial performance

How have Aileron Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.28M
Net income
-$15.73M
Gross margin
N/A
Net margin
N/A
Aileron Therapeutics's net income has increased by 42% YoY but it has decreased by 22% from the previous quarter
The operating income has increased by 41% year-on-year but it has declined by 19% since the previous quarter

Growth

What is Aileron Therapeutics's growth rate over time

Valuation

What is Aileron Therapeutics stock price valuation
P/E
N/A
P/B
3.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 43% year-on-year but it is down by 20% since the previous quarter
ALRN's P/B is 132% above its 5-year quarterly average of 1.4
Aileron Therapeutics's equity has shrunk by 63% YoY and by 38% QoQ

Efficiency

How efficient is Aileron Therapeutics business performance
The ROA has soared by 53% YoY and by 46% from the previous quarter
The ROE has plunged by 53% from the previous quarter and by 35% YoY

Dividends

What is ALRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALRN.

Financial health

How did Aileron Therapeutics financials performed over time
The total liabilities has soared by 128% YoY
ALRN's quick ratio is down by 47% QoQ and by 37% YoY
The debt is 99% smaller than the equity
Aileron Therapeutics's equity has shrunk by 63% YoY and by 38% QoQ
The debt is up by 45% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.